ArticleLaboratory investigation; a journal of technical methods and pathology2013
Low doses of celecoxib attenuate gut barrier failure during experimental peritonitis.
Article in Laboratory investigation; a journal of technical methods and pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- An Adaptive Bayesian Design for Personalized Dosing in a Cancer Prevention Trial.American journal of preventive medicine · 2020Trial
- Cellulose Nanocrystal-Based Sulfatase-Responsive Hydrogel for Sustained Celecoxib Release in Ulcerative Colitis Therapy.Biomaterials research · 2026Article
- FXR deletion attenuates intestinal barrier dysfunction in murine acute intestinal inflammation.American journal of physiology. Gastrointestinal and liver physiology · 2024Article
- The severity of NEC is ameliorated by prostaglandin E2 through regulating intestinal microcirculation.Scientific reports · 2023Article
- Hydrogen-Rich Water Mitigates LPS-Induced Chronic Intestinal Inflammatory Response in Rats via Nrf-2 and NF-κB Signaling Pathways.Veterinary sciences · 2022Article
- Protective effect of berberine against LPS-induced injury in the intestine: a review.Cell cycle (Georgetown, Tex.) · 2022Review
- Effect of Celecoxib and Infliximab against Multiple Organ Damage Induced by Sepsis in Rats: A Comparative Study.Biomedicines · 2022Article
- Changes in Serum, Red Blood Cell, and Colonic Fatty Acids in a Personalized Omega-3 Fatty Acid Supplementation Trial.Nutrition and cancer · 2022Article
- Interkingdom Communication and Regulation of Mucosal Immunity by the Microbiome.The Journal of infectious diseases · 2021Review
- EP2 Receptor Blockade Attenuates COX-2 Upregulation During Intestinal Inflammation.Shock (Augusta, Ga.) · 2020Article
- Role of Rutin in 5-Fluorouracil-Induced Intestinal Mucositis: Prevention of Histological Damage and Reduction of Inflammation and Oxidative Stress.Molecules (Basel, Switzerland) · 2020Article
- Lipid mechanisms in hallmarks of cancer.Molecular omics · 2020Review
- Butyrate Mitigates Weanling Piglets From Lipopolysaccharide-Induced Colitis by Regulating Microbiota and Energy Metabolism of the Gut-Liver Axis.Frontiers in microbiology · 2020Article
- Protective Effect of Cashew Gum (Anacardium occidentale L.) on 5-Fluorouracil-Induced Intestinal Mucositis.Pharmaceuticals (Basel, Switzerland) · 2019Article
- Cyclooxygenase (COX)-2 Inhibitors ReduceFrontiers in microbiology · 2019Article
- Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms.American journal of physiology. Gastrointestinal and liver physiology · 2018Article
- Intra-abdominal infection combined with intra-abdominal hypertension aggravates the intestinal mucosal barrier dysfunction.Bioscience reports · 2018Article
- Pathogenesis of neonatal necrotizing enterocolitis.Pediatric surgery international · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
The intestinal barrier becomes compromised during systemic inflammation, leading to the entry of luminal bacteria into the host and gut origin sepsis. Pathogenesis and treatment of inflammatory gut barrier failure is an important problem in critical care. In this study, we examined the role of cyclooxygenase-2 (COX-2), a key enzyme in the production of inflammatory prostanoids, in gut barrier failure during experimental peritonitis in mice. I.p. injection of LPS or cecal ligation and puncture (CLP) increased the levels of COX-2 and its product prostaglandin E2 (PGE2) in the ileal mucosa, caused pathologic sloughing of the intestinal epithelium, increased passage of FITC-dextran and bacterial translocation across the barrier, and increased internalization of the tight junction (TJ)-associated proteins junction-associated molecule-A and zonula occludens-1. Luminal instillation of PGE2 in an isolated ileal loop increased transepithelial passage of FITC-dextran. Low doses (0.5-1 mg/kg), but not a higher dose (5 mg/kg) of the specific COX-2 inhibitor Celecoxib partially ameliorated the inflammatory gut barrier failure. These results demonstrate that high levels of COX-2-derived PGE2 seen in the mucosa during peritonitis contribute to gut barrier failure, presumably by compromising TJs. Low doses of specific COX-2 inhibitors may blunt this effect while preserving the homeostatic function of COX-2-derived prostanoids. Low doses of COX-2 inhibitors may find use as an adjunct barrier-protecting therapy in critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.